JP2020535138A - グルカゴンおよびｇｌｐ−１受容体の長時間作用型コアゴニスト - Google Patents

グルカゴンおよびｇｌｐ−１受容体の長時間作用型コアゴニスト Download PDF

Info

Publication number
JP2020535138A
JP2020535138A JP2020516798A JP2020516798A JP2020535138A JP 2020535138 A JP2020535138 A JP 2020535138A JP 2020516798 A JP2020516798 A JP 2020516798A JP 2020516798 A JP2020516798 A JP 2020516798A JP 2020535138 A JP2020535138 A JP 2020535138A
Authority
JP
Japan
Prior art keywords
bound
lys
alpha
fatty
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020516798A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020535138A5 (enExample
Inventor
パラニ，アナンダン
デン，シャオリン
ヒュアン，チュンフェイ
ビアンキ，エリザベッタ
オルヴィエート，フェデリカ
ジュウ，ユーピン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Publication of JP2020535138A publication Critical patent/JP2020535138A/ja
Publication of JP2020535138A5 publication Critical patent/JP2020535138A5/ja
Priority to JP2023032146A priority Critical patent/JP2023071869A/ja
Priority to JP2023144460A priority patent/JP2023171744A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2020516798A 2017-09-25 2018-09-21 グルカゴンおよびｇｌｐ−１受容体の長時間作用型コアゴニスト Pending JP2020535138A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023032146A JP2023071869A (ja) 2017-09-25 2023-03-02 グルカゴンおよびｇｌｐ－１受容体の長時間作用型コアゴニスト
JP2023144460A JP2023171744A (ja) 2017-09-25 2023-09-06 グルカゴンおよびｇｌｐ－１受容体の長時間作用型コアゴニスト

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762562674P 2017-09-25 2017-09-25
US62/562,674 2017-09-25
PCT/US2018/052124 WO2019060660A1 (en) 2017-09-25 2018-09-21 CO-AGONISTS WITH EXTENDED ACTION OF GLUCAGON AND GLP-1 RECEPTORS

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2023032146A Division JP2023071869A (ja) 2017-09-25 2023-03-02 グルカゴンおよびｇｌｐ－１受容体の長時間作用型コアゴニスト
JP2023144460A Division JP2023171744A (ja) 2017-09-25 2023-09-06 グルカゴンおよびｇｌｐ－１受容体の長時間作用型コアゴニスト

Publications (2)

Publication Number Publication Date
JP2020535138A true JP2020535138A (ja) 2020-12-03
JP2020535138A5 JP2020535138A5 (enExample) 2021-10-07

Family

ID=65810991

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020516798A Pending JP2020535138A (ja) 2017-09-25 2018-09-21 グルカゴンおよびｇｌｐ−１受容体の長時間作用型コアゴニスト
JP2023032146A Pending JP2023071869A (ja) 2017-09-25 2023-03-02 グルカゴンおよびｇｌｐ－１受容体の長時間作用型コアゴニスト
JP2023144460A Pending JP2023171744A (ja) 2017-09-25 2023-09-06 グルカゴンおよびｇｌｐ－１受容体の長時間作用型コアゴニスト

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023032146A Pending JP2023071869A (ja) 2017-09-25 2023-03-02 グルカゴンおよびｇｌｐ－１受容体の長時間作用型コアゴニスト
JP2023144460A Pending JP2023171744A (ja) 2017-09-25 2023-09-06 グルカゴンおよびｇｌｐ－１受容体の長時間作用型コアゴニスト

Country Status (11)

Country Link
US (1) US11566057B2 (enExample)
EP (1) EP3700550A4 (enExample)
JP (3) JP2020535138A (enExample)
KR (1) KR102505628B1 (enExample)
CN (1) CN111132690A (enExample)
AU (1) AU2018338184B2 (enExample)
BR (1) BR112020005841A8 (enExample)
CA (2) CA3076496A1 (enExample)
MA (1) MA50474A (enExample)
MX (1) MX2020003217A (enExample)
WO (1) WO2019060660A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021078912A1 (en) * 2019-10-22 2021-04-29 Nuritas Limited Treatment of non-alcoholic fatty liver disease
EP3842060A1 (en) 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Stapled lactam co-agonists of the glucagon and glp-1 receptors
EP3842061A1 (en) 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Stapled triazole co-agonists of the glucagon and glp-1 receptors
EP3842449A1 (en) 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Stapled olefin co-agonists of the glucagon and glp-1 receptors
US12122817B2 (en) * 2020-09-22 2024-10-22 Serpentide Inc. Long-lasting GLP1 analogue drug for type-2 diabetes
IL304214B2 (en) 2021-01-20 2025-01-01 Viking Therapeutics Inc Compositions and methods for treating metabolic and liver disorders
EP4376871A1 (en) * 2021-07-30 2024-06-05 Boehringer Ingelheim International GmbH Dose regimen for long-acting glp1/glucagon receptor agonists
KR102873595B1 (ko) 2021-09-15 2025-10-22 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 장애의 치료를 위한 조성물 및 방법
CN117586373A (zh) * 2022-08-10 2024-02-23 成都奥达生物科技有限公司 一种长效双激动剂化合物
WO2024165571A2 (en) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function
WO2024252366A1 (en) * 2023-06-09 2024-12-12 Sun Pharmaceutical Industries Limited Glp-1/gip dual, glp-1/gcg dual and glp-1/gip/gcg triple receptor agonists
WO2025125576A2 (en) 2023-12-15 2025-06-19 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025133348A1 (en) 2023-12-22 2025-06-26 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025196502A1 (en) 2024-03-20 2025-09-25 North Carolina Agricultural & Technical State University Choline kinase inhibitors as a therapeutic treatment for obesity

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006523659A (ja) * 2003-04-16 2006-10-19 セルテック アール アンド ディ リミテッド ケモカイン受容体の調節物質としての環式第四級アミノ誘導体
WO2017074798A2 (en) * 2015-10-27 2017-05-04 Merck Sharp & Dohme Corp. Long-acting co-agonists of the glucagon and glp-1 receptors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US6852690B1 (en) 1995-08-22 2005-02-08 Amylin Pharmaceuticals, Inc. Method and composition for enhanced parenteral nutrition
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
PL1891105T3 (pl) 2005-06-13 2012-09-28 Imperial Innovations Ltd Analogi oksyntomoduliny i ich wpływ na zachowania żywieniowe
JP6017754B2 (ja) 2007-02-15 2016-11-02 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ グルカゴン／ｇｌｐ−１受容体コアゴニスト
CA2728284C (en) 2008-06-17 2019-09-10 Richard D. Dimarchi Glucagon/glp-1 receptor co-agonists
WO2010096052A1 (en) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
EP2723766A4 (en) 2011-06-22 2015-05-20 Univ Indiana Res & Tech Corp COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR
PH12013502671A1 (en) 2011-06-22 2022-04-08 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists
CA3093383A1 (en) 2014-10-24 2016-04-28 Merck Sharp & Dohme Corp. Co-agonists of the glucagon and glp-1 receptors
EP3430033A4 (en) * 2016-03-18 2019-11-20 Merck Sharp & Dohme Corp. CONJUGATES OF INSULIN-INCRETIN

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006523659A (ja) * 2003-04-16 2006-10-19 セルテック アール アンド ディ リミテッド ケモカイン受容体の調節物質としての環式第四級アミノ誘導体
WO2017074798A2 (en) * 2015-10-27 2017-05-04 Merck Sharp & Dohme Corp. Long-acting co-agonists of the glucagon and glp-1 receptors

Also Published As

Publication number Publication date
MX2020003217A (es) 2020-07-29
EP3700550A1 (en) 2020-09-02
JP2023171744A (ja) 2023-12-05
RU2020114220A3 (enExample) 2021-12-28
EP3700550A4 (en) 2022-02-23
MA50474A (fr) 2020-09-02
RU2020114220A (ru) 2021-10-27
CN111132690A (zh) 2020-05-08
BR112020005841A2 (pt) 2020-11-17
KR20200057059A (ko) 2020-05-25
WO2019060660A1 (en) 2019-03-28
US11566057B2 (en) 2023-01-31
JP2023071869A (ja) 2023-05-23
AU2018338184A1 (en) 2020-03-12
AU2018338184B2 (en) 2023-04-13
KR102505628B1 (ko) 2023-03-02
US20200270325A1 (en) 2020-08-27
CA3076496A1 (en) 2019-03-28
BR112020005841A8 (pt) 2023-04-11
CA3220650A1 (en) 2019-03-28

Similar Documents

Publication Publication Date Title
KR102505628B1 (ko) 글루카곤 및 glp-1 수용체의 장기-작용성 공-효능제
JP6581656B2 (ja) グルカゴンおよびｇｌｐ−１受容体のコアゴニスト
US11773150B2 (en) Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors
US11492385B2 (en) Long-acting co-agonists of the glucagon and GLP-1 receptors
CN115226391A (zh) 胰高血糖素和glp-1受体的钉合三唑共激动剂
RU2779314C2 (ru) Коагонисты рецепторов глюкагона и glp-1 длительного действия
EP4081244B1 (en) Stapled olefin co-agonists of the glucagon and glp-1 receptors
CN114867742A (zh) 胰高血糖素和glp-1受体的钉合内酰胺共激动剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210830

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210830

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220906

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20220916

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230302

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230906

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230913

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20231102